HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Heart 2008;94:395-397; doi:10.1136/hrt.2007.136002
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Patrignani, P.
Right arrow Articles by Tacconelli, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patrignani, P.
Right arrow Articles by Tacconelli, S.

FEATURED EDITORIAL

NSAIDs and cardiovascular disease

Paola Patrignani, Marta L Capone, Stefania Tacconelli

Department of Medicine and Center of Excellence on Aging, "G d’Annunzio" University, and CeSI, Italy

Correspondence to:
Dr P Patrignani, Department of Medicine and Center of Excellence on Aging, "G d’Annunzio" University, Via dei Vestini, 31, 66013 Chieti, Italy; ppatrignani@unich.it

The first 150 words of the full text of this article appear below.

Non-steroidal anti-inflammatory drugs (NSAIDs) are a chemically heterogeneous group of agents to treat symptoms of acute pain and chronic inflammatory and degenerative joint diseases, such as rheumatoid arthritis (RA) and osteoarthritis (OA).1 They act mostly through the inhibition of cyclooxygenase-2 (COX-2)-dependent prostanoids. They comprise traditional (t) NSAIDs and NSAIDs selective for COX-2, named cyclooxygenase-2 inhibitors, developed to reduce the gastrointestinal (GI) toxicity of tNSAIDs, which is dependent, at least in part, on the inhibition of COX-1.

Placebo-controlled trials have established that cyclooxygenase-2 inhibitors (rofecoxib, valdecoxib and celecoxib) confer a small but absolute increase in the incidence of thrombotic vascular events.2 An overview of data derived from trials with cyclooxygenase-2 inhibitors suggests that myocardial infarction (MI) predominates over stroke.3 The cardiovascular (CV) hazard associated with the use of cyclooxygenase-2 inhibitors led to the voluntary withdrawal from the United States (US) and European Union (EU) markets of rofecoxib and valdecoxib, in 2004 . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Cardiovascular Society